Co-Authors
This is a "connection" page, showing publications co-authored by Désirée Larenas-Linnemann and Torsten Zuberbier.
Connection Strength
1.515
-
Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care? J Allergy Clin Immunol Pract. 2019 Nov - Dec; 7(8):2511-2523.
Score: 0.210
-
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018 07; 73(7):1393-1414.
Score: 0.194
-
Work productivity in rhinitis using cell phones: The MASK pilot study. Allergy. 2017 Oct; 72(10):1475-1484.
Score: 0.180
-
Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2 LEN consensus. Allergy. 2021 08; 76(8):2354-2366.
Score: 0.059
-
COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper. Allergy. 2021 03; 76(3):648-676.
Score: 0.058
-
Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19. Int Arch Allergy Immunol. 2021; 182(4):324-338.
Score: 0.058
-
Spices to Control COVID-19 Symptoms: Yes, but Not Only…. Int Arch Allergy Immunol. 2021; 182(6):489-495.
Score: 0.057
-
Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? Clin Transl Allergy. 2020; 10:44.
Score: 0.057
-
Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. Allergy. 2020 10; 75(10):2440-2444.
Score: 0.057
-
ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020). Allergy. 2021 03; 76(3):689-697.
Score: 0.056
-
Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. Allergy. 2020 07; 75(7):1546-1554.
Score: 0.056
-
Is diet partly responsible for differences in COVID-19 death rates between and within countries? Clin Transl Allergy. 2020; 10:16.
Score: 0.055
-
MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clin Transl Allergy. 2018; 8:45.
Score: 0.049
-
Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study. Allergy. 2018 08; 73(8):1622-1631.
Score: 0.048
-
Treatment of allergic rhinitis using mobile technology with real-world data: The MASK observational pilot study. Allergy. 2018 09; 73(9):1763-1774.
Score: 0.048
-
CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report. Clin Transl Allergy. 2017; 7:37.
Score: 0.046
-
The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study. Allergy. 2018 02; 73(2):505-510.
Score: 0.046
-
The Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) Questionnaire Using Mobile Technology: The MASK Study. J Investig Allergol Clin Immunol. 2018; 28(1):42-44.
Score: 0.046
-
Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project). Allergy. 2018 Jan; 73(1):77-92.
Score: 0.046
-
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017 Oct; 140(4):950-958.
Score: 0.045
-
Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future - an EAACI Position Paper. Allergy. 2017 Jul; 72(7):1035-1042.
Score: 0.045